In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides
- PMID: 1741256
- PMCID: PMC310371
- DOI: 10.1093/nar/20.2.307
In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides
Abstract
Development of oligonucleotide derivatives as therapeutic agents requires an understanding of their pharmacokinetic behavior. The in vivo disposition and stability of a prototype of such compounds are reported here. The compound studied, a relatively G-rich 38 base 3' phosphopropyl amine oligonucleotide (TFO-1), was cleared from the circulation with a half-life of approximately 10 minutes, displaying distribution kinetics consistent with a two compartment model. TFO-1 was also readily absorbed into circulation from the peritoneal cavity. All tissues examined except brain accumulated the compound reaching concentrations calculated to be in the micromolar range. TFO-1 was found to be stable in circulation and in tissues in that a large fraction of intact material was detected 8 hours after injection, as assessed by gel electrophoresis. Approximately 20-30% of the injected dose was excreted in the urine over an 8 hour period. These results suggest that G-rich oligonucleotides, minimally modified at the 3' end, are relatively stable in vivo and have distribution kinetics favorable to use as therapeutic agents.
Similar articles
-
Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.Oncol Res. 1994;6(6):243-9. Oncol Res. 1994. PMID: 7865900
-
Penetration of oligonucleotides into mouse organism through mucosa and skin.FEBS Lett. 1993 Aug 2;327(3):271-4. doi: 10.1016/0014-5793(93)81002-h. FEBS Lett. 1993. PMID: 8348953
-
In vivo disposition and stability of DNA frayed wires in mice.Int J Biol Macromol. 2006 Nov 15;39(4-5):310-6. doi: 10.1016/j.ijbiomac.2006.05.001. Epub 2006 May 12. Int J Biol Macromol. 2006. PMID: 16777215
-
Pharmacokinetics of antisense oligonucleotides.Clin Pharmacokinet. 1995 Jan;28(1):7-16. doi: 10.2165/00003088-199528010-00002. Clin Pharmacokinet. 1995. PMID: 7712663 Review.
-
Clinical pharmacokinetics of amiodarone.Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002. Clin Pharmacokinet. 1984. PMID: 6370540 Review.
Cited by
-
Facile preparation of nuclease resistant 3' modified oligodeoxynucleotides.Nucleic Acids Res. 1993 Jan 11;21(1):145-50. doi: 10.1093/nar/21.1.145. Nucleic Acids Res. 1993. PMID: 8382790 Free PMC article.
-
Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3'hydroxypropylamine oligonucleotide.Nucleic Acids Res. 1994 Mar 25;22(6):977-86. doi: 10.1093/nar/22.6.977. Nucleic Acids Res. 1994. PMID: 8152930 Free PMC article.
-
Inhibition of transcription and antiproliferative effects in a cancer cell line using antigene oligonucleotides containing artificial nucleoside analogues.RSC Med Chem. 2023 May 26;14(8):1482-1491. doi: 10.1039/d3md00139c. eCollection 2023 Aug 16. RSC Med Chem. 2023. PMID: 37593572 Free PMC article.
-
Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine.Nucleic Acids Res. 1997 Feb 1;25(3):633-40. doi: 10.1093/nar/25.3.633. Nucleic Acids Res. 1997. PMID: 9016606 Free PMC article.
-
DNA triple helices: biological consequences and therapeutic potential.Biochimie. 2008 Aug;90(8):1117-30. doi: 10.1016/j.biochi.2008.02.011. Epub 2008 Feb 21. Biochimie. 2008. PMID: 18331847 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources